Loading
NASDAQHealthcareBiotechnology
Latest quote
$108.35
+$2.37 · +2.24%
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Previous close
$108.35
+$2.37 · +2.24%
Pre-market
$107.05
−$1.30 · -1.20%
Oct 8, 4:01 AM ET
Regular session · ET · Market data may be delayed.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Day range
Current $108.35
52-week range
Current $108.35
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
44
Mixed
Risk
51
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Day range
Current $108.35
52-week range
Current $108.35
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 39.2M USD | 47.07M USD | 78.59M USD | 46.83M USD | 72.83M USD |
| Gross profit | 39.2M USD | 47.07M USD | 78.59M USD | 46.83M USD | 72.83M USD |
| Research and development | 316.6M USD | 240.25M USD | 189.08M USD | 164.25M USD | 137.02M USD |
| Selling, general, and administrative | 68.2M USD | 63.53M USD | 55.04M USD | 43.83M USD | 36.35M USD |
| Operating expenses | 388.6M USD | 308.71M USD | 244.12M USD | 208.08M USD | 173.36M USD |
| Interest income | 38.03M USD | 38.03M USD | 18.76M USD | 6.62M USD | 488K USD |
| Interest expense | 249K USD | 249K USD | 196K USD | 176K USD | 175K USD |
| Depreciation and amortization | 8.31M USD | 7.37M USD | 3.57M USD | 2.98M USD | 2.4M USD |
| Operating income | −349.4M USD | −261.64M USD | −165.53M USD | −161.26M USD | −100.53M USD |
| Net income | −311.4M USD | −223.86M USD | −146.96M USD | −154.81M USD | −100.22M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$138.07
27.43% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI248.79M0.01%2.3T USD0.03%$381.03-0.40%
Vanguard Morningstar Small-Cap ETFVB179.93M0.10%185.3B USD0.03%$286.98-1.41%
iShares Russell 2000 ETFIWM173.29M0.22%78.56B USD0.19%$277.7-1.29%
State Street SPDR S&P Biotech ETFXBI118.78M1.15%10.08B USD0.35%$150.23-0.44%
Vanguard Morningstar Small-Cap Growth ETFVBK103.26M0.23%44.7B USD0.05%$342.24-1.50%
Vanguard Extended Market ETFVXF87.46M0.09%95.4B USD0.05%$233.49-1.56%
iShares Biotechnology ETFIBB59.86M0.58%10.4B USD0.44%$203.34+0.12%
iShares Russell 2000 Growth ETFIWO51.37M0.36%14.25B USD0.24%$355.37-1.43%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
